NCT02047253View on ClinicalTrials.gov

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 8, 2017

Study Completion Date

July 14, 2017

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Carfilzomib

Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.

DRUG

Dexamethasone

Administered prior to administration of Study drug

DRUG

Acyclovir

Administered orally twice daily

Trial Locations (4)

31210

Cancer Life Center, Navicent Health, Macon

35233

Birmingham VA Medical Center, Birmingham

35294

University of Alabama at Birmingham, Birmingham

70118

University of Tulane, New Orleans

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University of Alabama at Birmingham

OTHER